



IFW


FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

June 18, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
June 18, 2004	
Date	Steven L. Highlander

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/824,771 entitled "ASSAY FOR PHOSPHODIESTERASE FUNCTION" – Jackie D. Corbin and Sharron H. Francis*
Our reference: VBLT:034US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C10.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:034US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jackie D. Corbin

Sharron H. Francis

Serial No.: 10/824,771


Filed: April 15, 2004

For: ASSAY FOR PHOSPHODIESTERASE
FUNCTION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: VBLT:034US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
June 18, 2004	
Date	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/VBLT:034US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201


Date: June 18, 2004

Form PTO-1449 (modified)

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Atty. Docket No.

VBLT:034US

Serial No.

10/824,771

Applicant

Jackie D. Corbin

Sharron H. Francis

Filing Date:

April 15, 2004

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ballard <i>et al.</i> , "Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotied phosphodiesterase isozymes," <i>J. Urol.</i> , 159:2164-2171, 1998.
	C2	Corbin <i>et al.</i> , "Phosphorylation of phosphodiesterase-5 by cyclic meucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities," <i>Eur. J. Biochem.</i> , 267:2760-2767, 2000.
	C3	Corbin <i>et al.</i> , "[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP," <i>Mol. Pharmacol.</i> , 63(6):1364-1372, 2003.
	C4	Corbin and Francis, "Cyclic GMP phosphodiesterase-5: target of sildenafil," <i>J. Biol. Chem.</i> , 274(20):13729-13732, 1999.
	C5	Francis <i>et al.</i> , "Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity," <i>J. Biol. Chem.</i> , 277(49):47581-47587, 2002.
	C6	Francis <i>et al.</i> , "Single step isolation of sildenafil from commercially available Viagra tablets," <i>Int. J. Impot. Res.</i> , 15(5):369-372, 2003.
	C7	Gopal <i>et al.</i> , "Allosteric sites of phosphodiesterase-5 (PDE5): a potential role in negative feedback regulationo f cGMP signaling in corpus cavernosum," <i>Eur. J. Biochem.</i> , 268:3304-3312, 2001.

25416784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. VBLT:034US	Serial No. 10/824,771
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Jackie D. Corbin Sharron H. Francis	
		Filing Date: April 15, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Okada and Asakawa, "Allosteric activation of cGMP-specific, cGMP-binding phosphodiesterase (PDE5) by cGMP," <i>Biochemistry</i> , 41:9672-9679, 2002.
	C9	Saenz de Tajada <i>et al.</i> , "The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil," <i>Int. J. Impot. Res.</i> , 13(5):282-290, 2001.
	C10	Turko <i>et al.</i> , "Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds," <i>Mol. Pharmacol.</i> , 56:124-130, 1999.

25416784.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.